That's exactly the point and wishful thinking on your part. You are waiting for a better price and trying to convince everyone else that this stock should be heading to your ideal reentry price of $5.70 - $6.40 bottom.
The real point is why should RPRX revisit the last low with further clinical risks removed from the excellent trial data in December.